Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132198 | 0.91 | NPC1 (0.57) | POLBNPC1RIPK1EPHX2SMN1; SMN2 | |
| SCHEMBL25884649 | 0.91 | EPHX2 (0.63) | POLBNPC1TDP1RIPK1EPHX2 | |
| SCHEMBL14646676 | 0.82 | TACR1 (0.59) | POLBNPC1TDP1PARP1FKBP1A | |
| SCHEMBL17026995 | 0.77 | RIPK1 (0.67) | POLBRIPK1EPHX2 | |
| SCHEMBL2038120 | 0.76 | EPHX2 (0.59) | POLBRIPK1EPHX2HPGDL3MBTL1 | |
| SCHEMBL28303699 | 0.76 | EPHX2 (0.59) | POLBRIPK1EPHX2HPGDL3MBTL1 | |
| SCHEMBL13370801 | 0.76 | EPHX2 (0.59) | POLBRIPK1EPHX2HPGDL3MBTL1 | |
| SCHEMBL18922669 | 0.75 | GBA1 (0.52) | POLBNPC1TDP1FKBP1ASIGMAR1 | |
| SCHEMBL20905497 | 0.75 | RIPK1 (0.61) | NPC1RIPK1EPHX2MEN1RAB9A | |
| SCHEMBL1786176 | 0.75 | CHRNA7 (0.54) | POLBNPC1TDP1FKBP1AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912329-B2 | Composition for treatment of tuberculosis | BioVersys AG (CH) | 2014-12-16 | — | — | US | disclosed |
| EP-2445495-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | Bioversys AG (CH) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BioVersys AG (CH) | 2012-04-26 | — | — | US | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149761-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | BIOVERSYS GMBH (CH) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101080-A1 | COMPOSITION FOR TREATMENT OF TUBERCULOSIS | PRMT7, NCOA3, PRMT3 | POLB 1117/4885NPC1 3372/4885TDP1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.